[18F]-PI2620

DRUG2 trials

Sponsors

Life Molecular Imaging GmbH

Conditions

Alzheimer DiseaseProgressive Supranuclear Palsy

Phase 1

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

CompletedNCT04715750

Life Molecular Imaging GmbHAlzheimer Disease, Progressive Supranuclear Palsy

Start: 2020-11-12End: 2022-10-26Updated: 2025-05-18

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

CompletedNCT05187546

Life Molecular Imaging GmbHProgressive Supranuclear Palsy

Start: 2022-03-10End: 2024-03-05Updated: 2025-05-18